These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 20609248)
1. Adenovirus F protein as a delivery vehicle for botulinum B. Clapp B; Golden S; Maddaloni M; Staats HF; Pascual DW BMC Immunol; 2010 Jul; 11():36. PubMed ID: 20609248 [TBL] [Abstract][Full Text] [Related]
2. Mucosal vaccine targeting improves onset of mucosal and systemic immunity to botulinum neurotoxin A. Maddaloni M; Staats HF; Mierzejewska D; Hoyt T; Robinson A; Callis G; Kozaki S; Kiyono H; McGhee JR; Fujihashi K; Pascual DW J Immunol; 2006 Oct; 177(8):5524-32. PubMed ID: 17015739 [TBL] [Abstract][Full Text] [Related]
3. Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication. Jun S; Clapp B; Zlotkowska D; Hoyt T; Holderness K; Maddaloni M; Pascual DW Int Immunol; 2012 Feb; 24(2):117-28. PubMed ID: 22207133 [TBL] [Abstract][Full Text] [Related]
4. Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits. Staats HF; Fielhauer JR; Thompson AL; Tripp AA; Sobel AE; Maddaloni M; Abraham SN; Pascual DW PLoS One; 2011 Jan; 6(1):e16532. PubMed ID: 21304600 [TBL] [Abstract][Full Text] [Related]
5. Enhancing toxin-based vaccines against botulism. Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477 [TBL] [Abstract][Full Text] [Related]
6. An adenoviral vector-based mucosal vaccine is effective in protection against botulism. Xu Q; Pichichero ME; Simpson LL; Elias M; Smith LA; Zeng M Gene Ther; 2009 Mar; 16(3):367-75. PubMed ID: 19129860 [TBL] [Abstract][Full Text] [Related]
7. Expression of Hc fragment from Clostridium botulinum neurotoxin serotype B in Escherichia coli and its use as a good immunogen. Gao YL; Gao S; Kang L; Nie C; Wang JL Hum Vaccin; 2010 Jun; 6(6):462-6. PubMed ID: 20519939 [TBL] [Abstract][Full Text] [Related]
8. Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. Zeng M; Xu Q; Elias M; Pichichero ME; Simpson LL; Smith LA Vaccine; 2007 Oct; 25(43):7540-8. PubMed ID: 17897756 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine. Yu YZ; Li N; Wang RL; Zhu HQ; Wang S; Yu WY; Sun ZW Clin Vaccine Immunol; 2008 Dec; 15(12):1819-23. PubMed ID: 18845829 [TBL] [Abstract][Full Text] [Related]
11. Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E. Shi DY; Liu FJ; Mao YY; Cui RT; Lu JS; Yu YZ; Dong XJ; Yang ZX; Sun ZW; Pang XB Hum Vaccin Immunother; 2020; 16(1):100-108. PubMed ID: 31210561 [TBL] [Abstract][Full Text] [Related]
12. Mechanisms of enhanced neutralization of botulinum neurotoxin by monoclonal antibodies conjugated to antibodies specific for the erythrocyte complement receptor. Sharma R; Zhao H; Al-Saleem FH; Ubaid AS; Puligedda RD; Segan AT; Lindorfer MA; Bermudez R; Elias M; Adekar SP; Simpson LL; Taylor RP; Dessain SK Mol Immunol; 2014 Feb; 57(2):247-54. PubMed ID: 24184879 [TBL] [Abstract][Full Text] [Related]
13. Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system. Yu Y; Shi D; Liu S; Gong ZW; Wang S; Sun Z Hum Vaccin Immunother; 2015; 11(2):468-73. PubMed ID: 25483668 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system. Zichel R; Mimran A; Keren A; Barnea A; Steinberger-Levy I; Marcus D; Turgeman A; Reuveny S Clin Vaccine Immunol; 2010 May; 17(5):784-92. PubMed ID: 20357058 [TBL] [Abstract][Full Text] [Related]
15. Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F. Yu YZ; Zhang SM; Ma Y; Zhu HQ; Wang WB; Du Y; Zhou XW; Wang RL; Wang S; Yu WY; Huang PT; Sun ZW Clin Immunol; 2010 Nov; 137(2):271-80. PubMed ID: 20696619 [TBL] [Abstract][Full Text] [Related]
16. Alternative vaccination against equine botulism (BoNT/C). Frey J; Eberle S; Stahl C; Mazuet C; Popoff M; Schatzmann E; Gerber V; Dungu B; Straub R Equine Vet J; 2007 Nov; 39(6):516-20. PubMed ID: 18065309 [TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity. Khouri JM; Motter RN; Arnon SS Vaccine; 2018 Apr; 36(15):2041-2048. PubMed ID: 29475762 [TBL] [Abstract][Full Text] [Related]
18. Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism. Webb RP; Smith TJ; Smith LA; Wright PM; Guernieri RL; Brown JL; Skerry JC Toxins (Basel); 2017 Sep; 9(9):. PubMed ID: 28869522 [TBL] [Abstract][Full Text] [Related]
19. Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes. Shone C; Agostini H; Clancy J; Gu M; Yang HH; Chu Y; Johnson V; Taal M; McGlashan J; Brehm J; Tong X Infect Immun; 2009 Jul; 77(7):2795-801. PubMed ID: 19398544 [TBL] [Abstract][Full Text] [Related]
20. Oral vaccination with an adenovirus-vectored vaccine protects against botulism. Chen S; Xu Q; Zeng M Vaccine; 2013 Feb; 31(7):1009-11. PubMed ID: 23295065 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]